Table 5.
Univariate Analysis of Factors Associated With GH and IGF-1 Response for 90 Eligible Studies
| Variables | Comparison of Response Rates |
|||||
|---|---|---|---|---|---|---|
| GH, % | 95% CI | P Value | IGF-1, % | 95% CI | P Value | |
| Study type | ||||||
| Retrospective | 56 | (47, 66) | .88 | 54 | (45, 62) | .84 |
| Prospective | 56 | (51, 61) | 55 | (51, 59) | ||
| Multicenter | 57 | (49, 66) | .58 | 55 | (47, 62) | 1.00 |
| Single center | 55 | (49, 60) | 55 | (50, 60) | ||
| Treatment type | ||||||
| Lantreotide | 59 | (50, 68) | .37 | 53 | (45, 61) | .46 |
| Octreotide | 55 | (49, 60) | 56 | (0, 61) | ||
| Preselection favorable | .09 | .12 | ||||
| Yes | 61 | (52, 70) | 59 | (51, 67) | ||
| No | 53 | (48, 58) | 53 | (48, 57) | ||
| Prior SRL therapy | .01 | .41 | ||||
| Yes | 64 | (55, 72) | 57 | (49, 64) | ||
| No | 52 | (47, 57) | 54 | (49, 58) | ||
| Switch study | .18 | .29 | ||||
| Yes | 63 | (51, 75) | 60 | (49, 70) | ||
| No | 54 | (50, 59) | 54 | (50, 58) | ||
| GH criteria | .94 | .75 | ||||
| <2.5 | 56 | (43, 70) | 56 | (44, 68) | ||
| 2.5 | 56 | (43, 69) | 53 | (41, 65) | ||
| >2.5 | 54 | (42, 66) | 54 | (44, 65) | ||
| Titration scheme | .10 | .40 | ||||
| Titrated | 55 | (46, 65) | 54 | (46, 62) | ||
| Fixed | 46 | (32, 60) | 50 | (37, 61) | ||
| Fixed/titrated | 61 | (54, 68) | 58 | (51, 64) | ||
| SRL therapy naïve, %a | .06 | .40 | ||||
| 100% SRL Rx naïve | 51 | (38, 63) | 53 | (43, 64) | ||
| 0% SRL Rx naïve | 63 | (53, 73) | 58 | (49, 67) | ||
Abbreviations: CI, confidence interval; Rx, therapy.
a
Extremes (100% SRL Rx naive: n = 38; 0% SRL Rx naive: n = 20).